This site is intended for Healthcare professionals only.

25% patients have residual pulmonary hypertension after Pulmonary endarterectomy


25% patients have residual pulmonary hypertension after Pulmonary endarterectomy

Pulmonary endarterectomy (PEA) is the standard treatment for chronic thromboembolic pulmonary hypertension (CTEPH), but the surgery leaves 25% of patients with residual pulmonary hypertension (RPH), according to a study published in the Journal of Thoracic and Cardiovascular Surgery.

Pulmonary endarterectomy is a surgical treatment for CTEPH. Although pulmonary endarterectomy is the treatment of choice in terms of both functional outcomes and survival, many patients experience persistent pulmonary hypertension after pulmonary endarterectomy.

Hsieh WC et al conducted a study to calculate the pooled estimates of outcomes after pulmonary endarterectomy including persistent pulmonary hypertension  (PPH).

The authors conducted a meta-analysis of published studies reporting residual/persistent/recurrent pulmonary hypertension in 4868 patients with CTEPH after pulmonary endarterectomy. The outcome was the rate of PPH and change in mean pulmonary artery pressure, pulmonary vascular resistance, and 6-minute walk distance after pulmonary endarterectomy.

The analysis revealed that :

  • RPH was diagnosed in 25% (95% CI, 0.18-0.34) of PEA-treated patients with CTEPH.
  • PEA lowered mean pulmonary artery pressure by 21.42 mmHg (standardized mean difference, 1.75).
  • PEA lowered mean pulmonary vascular resistance by 560.3 dyn.s/cm5(standardized mean difference, 1.64).
  • PEA increased 6-minute walk distance by a mean of 95.7 m

The study concluded that pulmonary endarterectomy is the standard of care for chronic thromboembolic pulmonary hypertension and provides immediate correction of hemodynamic parameters in most patients.

However, in up to 25% of operable cases, pulmonary hypertension persists after surgery. In those patients with persistent pulmonary hypertension, continued medical management with newer agents may be required to improve pulmonary hemodynamics and patient outcomes.

CTEPH is a long-term disease caused by a blockage in the blood vessels that deliver blood from the heart to the lungs resulting in increased pressure in these arteries. The blockage either results from a hardened blood clot that is thought to originate from the deep veins of the body (thromboembolism) and remains in the arteries, or from a scar that forms at the site where the clot has damaged the arteries, causing permanent fibrous obstruction (blood flow blockage).

For more reference log on to http://10.1016/j.jtcvs.2018.04.110

The following two tabs change content below.
Vinay Singh

Vinay Singh

Vinay Singh joined Medical Dialogue as Desk Editor in 2018. He covers the medical speciality news in different medical categories including Medical guidelines, updates from Medical Journals and Case Reports. He completed his graduation in Biotechnology from AAIDU and did his MBA from IILM Gurgaon. He can be contacted at editorial@medicaldialogues.in . Contact no. 011-43720751
Source: With inputs from Journal of Thoracic and Cardiovascular Surgery

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted